Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Advances in ALK-mutant NSCLC

Alessandra Bearz • 12 Sep 2022
ESMO 2022
Lung Cancer Non-Small Cell Lung Cancer Lorlatinib

Alessandra Bearz, MD, CRO National Cancer Institute, Aviano, Italy, discusses advances in ALK-mutant non-small cell lung cancer (NSCLC), the development of second and third-generation ALK inhibitors to overcome resistance, as well as novel compounds under investigation. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alessandra Bearz

1:06
Lung cancer highlights from ESMO 2022
Alessandra Bearz • 12 Sep 2022
0:45
Novel approaches in NSCLC
Alessandra Bearz • 12 Sep 2022
0:40
Areas of unmet need for patients with NSCLC and brain metastases
Alessandra Bearz • 12 Sep 2022
2:32
CROWN: CNS AEs do not increase in 3-year follow-up
Alessandra Bearz • 12 Sep 2022

Related Videos

2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
2:43
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl • 17 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals